Fig. 2
Association of decreased AGGF1 and increased ER stress signaling. a Representative immunohistochemical images for AGGF1 expression (left) in heart sections from eight dilated cardiomyopathy (DCM) patients and three controls (NC) and quantification (right; **P < 0.01). Scale bar, 100 μm. b Western blot analysis for AGGF1 and ER stress signaling markers using protein extracts from eight DCM patients and three controls (NC group: n = 3; DCM group: n = 8, **P < 0.01). c Real-time RT-PCR analysis for the level of AGGF1 mRNA in patients’ hearts (*P < 0.05). d Representative immunohistochemical images for AGGF1 expression (left) in heart sections from TAC mice vs. control Sham mice (12 weeks of age, 20–25 g) and quantification (right; n = 5/group, **P < 0.01). Scale bar, 50 μm. e Western blot analysis for AGGF1 and ER stress signaling markers using protein extracts from mice with ISO treatment vs. mice with control vehicle (Veh) treatment (n = 6/group, **P < 0.01). f Real-time RT-PCR analysis for the level of AGGF1 mRNA using cDNA extracts from mice with ISO treatment vs. mice with control vehicle (Veh) treatment (right; n = 5/group, **P < 0.01). g Western blot analysis for AGGF1 and ER stress signaling markers using protein extracts from H9C2 cells treated with or without ISO (n = 6/group, **P < 0.01). h Real-time RT-PCR analysis for the level of AGGF1 mRNA using RNA extracts from H9C2 cells treated with or without ISO (n = 3/group, **P < 0.01). Data are shown as the mean ± s.d. from at least three independent experiments. Statistical analysis was carried out by a Student’s two-tailed t-test
